The FDA has announced a voluntary recall of Chantix (varenicline) after routine quality checks detected elevated levels of nitrosamines in certain batches of the medication. Nitrosamines are chemicals that can naturally occur in small amounts in food and water, but higher concentrations in medications may pose long-term health risks.
According to the agency, the levels discovered in Chantix exceeded the FDA’s recommended safety threshold. Although the risk to patients remains low, regulators emphasized that even small increases above acceptable limits warrant immediate action to protect public health.
Chantix, commonly prescribed to help adults stop smoking, has been the subject of heightened monitoring in recent years as part of the FDA’s broader effort to reduce impurities in pharmaceuticals. The agency stressed that the recall is precautionary and does not suggest that all Chantix products are unsafe.
Patients currently taking the medication are advised not to stop abruptly without consulting a healthcare provider. Instead, they should speak with their doctor or pharmacist about safe alternatives and check whether their specific batch is included in the recall.
